Beta-adrenergic drugs and risk of Parkinson’s disease: A
systematic review and meta-analysis

J 2022

Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis

SINGH, Ambrish; Mohammad Salman HUSSAIN; Sreelatha AKKALA; Jitka KLUGAROVÁ; Andrea POKORNÁ et. al.

Základní údaje

Originální název

Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis

Autoři

SINGH, Ambrish; Mohammad Salman HUSSAIN; Sreelatha AKKALA; Jitka KLUGAROVÁ; Andrea POKORNÁ; Miloslav KLUGAR; E. Haydn WALTERS; Ingrid HOPPER; Julie A. CAMPBELL; Bruce TAYLOR a Benny ANTONY

Vydání

AGEING RESEARCH REVIEWS, CLARE, ELSEVIER IRELAND LTD, 2022, 1568-1637

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 13.100

Kód RIV

RIV/00216224:14110/22:00127142

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1016/j.arr.2022.101670

UT WoS

000841188700006

EID Scopus

2-s2.0-85133352138

Klíčová slova anglicky

Beta-adrenoceptors; Beta-blockers; Beta -antagonist; Beta-agonist; Propranolol; Salbutamol; Parkinson ?s disease

Štítky

14110611, 14119612, 14119613, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 14. 11. 2022 08:37, Mgr. Tereza Miškechová

Anotace

V originále

Background: Parkinson's Disease (PD) is a neurodegenerative disorder manifested by rest tremor, rigidity, bradykinesia, and postural instability. Recent pharmaco-epidemiological studies evaluating beta-adrenergic drug use and risk of PD have reported conflicting findings. Objectives: This systematic review and meta-analyses evaluate the association between beta-adrenergic (agonists and antagonists) drugs' use and PD. Methods: An electronic literature search of eight databases was performed from inception to July 2021 to identify pharmaco-epidemiological studies (case-control and cohort) reporting the risk of PD in beta-adrenergic users compared to non-users. We used the generic inverse variance method and RevMan (5.3.5) to estimate pooled adjusted risk ratios (aRRs) of PD using a random-effects model. Results: Of 3168 records, 15 studies (10 case-control; five cohort) with 6508,877 participants, including 87,011 PD cases, were included. In the pooled analysis (n = 10) including any beta-antagonist users, compared with nonusers, the aRR for PD was 1.19 (CI: 1.05,1.35); for any beta-agonist users (n = 8) aRR for PD was 0.87 (CI: 0.78,0.97). Propranolol users had a significantly increased risk of PD (aRR:1.91; CI:1.20,3.06), whereas salbutamol use was associated with reduced risk of PD (aRR:0.95; CI:0.92,0.99). Significant heterogeneity (I2 >87%) was observed, but the majority (n = 13) of the studies were of high quality, based on the JBI tool. Conclusions: Beta-antagonist use was associated with a modestly increased risk of PD, whereas beta-agonist use was associated with a modest decreased risk of PD. Future epidemiological studies should address the issues of protopathic bias and indirect association using appropriate epidemiological methods.

Návaznosti

EF18_053/0016952, projekt VaV

Název: Postdoc2MUNI

LTC20031, projekt VaV

Název: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic, INTER-COST

Citovat

SINGH, Ambrish; Mohammad Salman HUSSAIN; Sreelatha AKKALA; Jitka KLUGAROVÁ; Andrea POKORNÁ; Miloslav KLUGAR; E. Haydn WALTERS; Ingrid HOPPER; Julie A. CAMPBELL; Bruce TAYLOR a Benny ANTONY. Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis. AGEING RESEARCH REVIEWS. CLARE: ELSEVIER IRELAND LTD, 2022, roč. 80, September 2022, s. 1-13. ISSN 1568-1637. Dostupné z: https://doi.org/10.1016/j.arr.2022.101670.

@article{2231684,
   author = {Singh, Ambrish and Hussain, Mohammad Salman and Akkala, Sreelatha and Klugarová, Jitka and Pokorná, Andrea and Klugar, Miloslav and Walters, E. Haydn and Hopper, Ingrid and Campbell, Julie A. and Taylor, Bruce and Antony, Benny},
   article_location = {CLARE},
   article_number = {September 2022},
   doi = {https://doi.org/10.1016/j.arr.2022.101670},
   keywords = {Beta-adrenoceptors; Beta-blockers; Beta -antagonist; Beta-agonist; Propranolol; Salbutamol; Parkinson ?s disease},
   language = {eng},
   issn = {1568-1637},
   journal = {AGEING RESEARCH REVIEWS},
   title = {Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis},
   url = {https://www.sciencedirect.com/science/article/pii/S156816372200112X?via%3Dihub},
   volume = {80},
   year = {2022}
}

TY  - JOUR
ID  - 2231684
AU  - Singh, Ambrish - Hussain, Mohammad Salman - Akkala, Sreelatha - Klugarová, Jitka - Pokorná, Andrea - Klugar, Miloslav - Walters, E. Haydn - Hopper, Ingrid - Campbell, Julie A. - Taylor, Bruce - Antony, Benny
PY  - 2022
TI  - Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis
JF  - AGEING RESEARCH REVIEWS
VL  - 80
IS  - September 2022
SP  - 1-13
EP  - 1-13
PB  - ELSEVIER IRELAND LTD
SN  - 15681637
KW  - Beta-adrenoceptors
KW  - Beta-blockers
KW  - Beta -antagonist
KW  - Beta-agonist
KW  - Propranolol
KW  - Salbutamol
KW  - Parkinson ?s disease
UR  - https://www.sciencedirect.com/science/article/pii/S156816372200112X?via%3Dihub
N2  - Background: Parkinson's Disease (PD) is a neurodegenerative disorder manifested by rest tremor, rigidity, bradykinesia, and postural instability. Recent pharmaco-epidemiological studies evaluating beta-adrenergic drug use and risk of PD have reported conflicting findings. Objectives: This systematic review and meta-analyses evaluate the association between beta-adrenergic (agonists and antagonists) drugs' use and PD. Methods: An electronic literature search of eight databases was performed from inception to July 2021 to identify pharmaco-epidemiological studies (case-control and cohort) reporting the risk of PD in beta-adrenergic users compared to non-users. We used the generic inverse variance method and RevMan (5.3.5) to estimate pooled adjusted risk ratios (aRRs) of PD using a random-effects model. Results: Of 3168 records, 15 studies (10 case-control; five cohort) with 6508,877 participants, including 87,011 PD cases, were included. In the pooled analysis (n = 10) including any beta-antagonist users, compared with nonusers, the aRR for PD was 1.19 (CI: 1.05,1.35); for any beta-agonist users (n = 8) aRR for PD was 0.87 (CI: 0.78,0.97). Propranolol users had a significantly increased risk of PD (aRR:1.91; CI:1.20,3.06), whereas salbutamol use was associated with reduced risk of PD (aRR:0.95; CI:0.92,0.99). Significant heterogeneity (I2 >87%) was observed, but the majority (n = 13) of the studies were of high quality, based on the JBI tool. Conclusions: Beta-antagonist use was associated with a modestly increased risk of PD, whereas beta-agonist use was associated with a modest decreased risk of PD. Future epidemiological studies should address the issues of protopathic bias and indirect association using appropriate epidemiological methods.
ER  -

SINGH, Ambrish; Mohammad Salman HUSSAIN; Sreelatha AKKALA; Jitka KLUGAROVÁ; Andrea POKORNÁ; Miloslav KLUGAR; E. Haydn WALTERS; Ingrid HOPPER; Julie A. CAMPBELL; Bruce TAYLOR a Benny ANTONY. Beta-adrenergic drugs and risk of Parkinson’s disease: A systematic review and meta-analysis. \textit{AGEING RESEARCH REVIEWS}. CLARE: ELSEVIER IRELAND LTD, 2022, roč.~80, September 2022, s.~1-13. ISSN~1568-1637. Dostupné z: https://doi.org/10.1016/j.arr.2022.101670.

Přehled o publikaci